Inkspace Imaging, Inc. appears in FDA device records as the applicant for a magnetic resonance specialty coil cleared under product code MOS. The supplied collection holds one linked 510(k) record, K262813, decided Substantially Equivalent on October 5, 2026, with a decision count of one SESE in both the full collection and the single-record sample. Earlier clearances for related body arrays appear in the numbered sources and show how the product line has been described to FDA over time. [1][3][5]

The 2026 clearance and its scope

K262813 covers the InkSpace Imaging Small Body Array (SBA12PH15x), received August 7, 2026 and decided October 5, 2026 as Substantially Equivalent under a Special clearance type. The FDA record lists the applicant as Inkspace Imaging, Inc. of Pleasanton, CA, with a Summary filed, the Radiology advisory committee, and no third-party review. The device is classified as a Coil, Magnetic Resonance, Specialty, Class II, under regulation number 892.1000. [1]

The public 510(k) database entry for K262813 confirms the same premarket notification pathway; the supplied page text is largely navigation and accessibility material rather than device-specific content. [2]

Earlier body array filings

A December 20, 2024 FDA letter addresses K243675 for the trade name InkSpace Imaging Small Body Array, regulation 21 CFR 892.1000, Class II, product code MOS, and names the InkSpace Imaging Small Body Array (K233444) as predicate. A January 8, 2024 letter addresses K233444 for the same trade name and regulation, naming the InkSpace Imaging Body Array (K223487) as predicate. [3][5]

The K233444 decision letter describes the Small Body Array as a phased array, receive-only coil intended to work with Siemens 3.0T MRI scanners to provide signal-to-noise ratio and uniformity for high resolution body MR imaging examinations. A December 8, 2022 letter covers K223487 for the InkSpace Imaging Body Array, Class II, product code MOS, with the generic name Coil, Magnetic Resonance, Specialty. [5][9]

How the company describes its products

InkSpace Imaging's own product page describes a 24-channel MR coil built with proprietary printed technology, positioned as the first body array designed for pediatric patients, with a flexible array for close fit and high coil density for parallel imaging. The same page references trademarks Snuggle, Silhouette and Nuzzle. These are company statements, not FDA findings. [4]

The company's about page states that it designs and manufactures lightweight, flexible MRI receive coils for pediatric, adult and veterinary applications. A January 11, 2024 company announcement describes FDA clearance of a 24-channel Small Body Array for Siemens Healthineers Magnetom Skyra and Vida series 3T scanners. [6][7]

Identity and attribution

FDA correspondence routes regulatory correspondence through Taras Bouzakine, Director, Regulatory Affairs at Veranex, Inc., a consultancy address, not a corporate parent. The applicant of record is Inkspace Imaging, Inc.; no parent, brand owner or headquarters is verified in the public documents, and filing addresses are not treated as headquarters. A homepage testimonial attributed to Wilson King, MD, of Saint Louis University School of Medicine is a clinician statement published by the company. [3][5][8]